312 related articles for article (PubMed ID: 23391111)
1. The genetics of neuroendocrine tumors.
Öberg K
Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
Capurso G; Archibugi L; Delle Fave G
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):594-601. PubMed ID: 25619712
[TBL] [Abstract][Full Text] [Related]
3. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
4. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
5. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Maxwell JE; Sherman SK; Howe JR
Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
[TBL] [Abstract][Full Text] [Related]
6. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
8. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
9. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
[TBL] [Abstract][Full Text] [Related]
11. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
12. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
14. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
[No Abstract] [Full Text] [Related]
15. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
17. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
19. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
20. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
